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Abstract: The morbidity and mortality benefits of lowering blood pressure (BP) in hypertensive 
patients are well established, with most individuals requiring multiple agents to achieve BP 
control. Considering the important role of the renin-angiotensin-aldosterone system (RAAS) in 
the pathophysiology of hypertension, a key component of combination therapy should include 
a RAAS inhibitor. Angiotensin receptor blockers (ARBs) lower BP, reduce cardiovascular risk, 
provide organ protection, and are among the best tolerated class of antihypertensive therapy. 
In this article, we discuss two ARB combinations (valsartan/hydrochlorothiazide [HCTZ] 
and amlodipine/valsartan), both of which are indicated for the treatment of hypertension in 
patients not adequately controlled on monotherapy and as initial therapy in patients likely to 
need multiple drugs to achieve BP goals. Randomized, double-blind studies that have assessed 
the antihypertensive efficacy and safety of these combinations in the first-line treatment of 
hypertensive patients are reviewed. Both valsartan/HCTZ and amlodipine/valsartan effectively 
lower BP and are well tolerated in a broad range of patients with hypertension, including 
difficult-to-treat populations such as those with severe BP elevations, prediabetes and diabetes, 
patients with the cardiometabolic syndrome, and individuals who are obese, elderly, or black. 
Also discussed herein are patient-focused perspectives related to the use of valsartan/HCTZ 
and amlodipine/valsartan, and the rationale for use of single-pill combinations as one approach 
to enhance patient compliance with antihypertensive therapy.
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Introduction
Almost one in three adults in the United States has hypertension,1 and it remains a 
significant risk factor for cardiovascular disease.1,2 Hypertension is associated with 
substantial morbidity and mortality.3 Target organs that may be affected include the 
heart, brain, vasculature, kidneys, and eyes. Persistent blood pressure (BP) elevation 
may result in an acceleration of atherosclerosis, coronary heart disease, heart failure, 
and renal failure.3 Although not fully established, there are also numerous reports 
of a possible relationship between hypertension and an increased risk of cognitive 
decline and vascular dementia.4 Hypertension is perhaps the most important individual 
and societal health burden in terms of costs and loss of quality-adjusted life years.5 
Although in recent years the proportion of hypertensive patients receiving treatment 
and the rate of BP control have increased, control rates still remain low.6 Results of 
the National Health and Nutrition Examination Survey (2003–2004) indicate that only 
approximately 37% of all hypertensive patients are controlled (systolic blood pressure 
[SBP]/diastolic blood pressure [DBP] 140/90 mmHg if nondiabetic or 130/80 Integrated Blood Pressure Control 2009:2 40
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mmHg if diabetic). Even among treated hypertensive patients, 
control rates are only about 57% and substantially lower 
among diabetics (38%).6 The management of hypertension 
is complicated by the fact that most of this population has 
additional comorbidities/cardiometabolic risk factors.7–11
It is recommended that lifestyle interventions (smoking 
cessation, weight loss, exercise, reductions in alcohol, salt, 
and fat intake, and increased fruit/vegetable consumption) 
be instituted whenever appropriate in all hypertensive 
patients.2,12 Unfortunately, long-term compliance with such 
measures is low,2 although well-designed community-based 
efforts were shown to reduce BP, to improve lifestyle choices 
and health habits, and to reduce levels of cardiovascular risk 
in the population.13,14 In addition to lifestyle interventions, 
most hypertensive patients will require antihypertensive 
therapy with a combination of agents to reach BP goals.2,15 For 
example, in ASCOT-BPLA, nearly 90% of participants were 
on multiple antihypertensive agents by the end of the trial.16 
Antihypertensive drugs of different classes can be combined 
if: they have different and complementary mechanisms of 
action; the efficacy of the combination is greater than that 
of either component; and the complementary mechanisms of 
action lead to a favorable tolerability profile. The advantages 
of this approach are that: low doses of the individual 
components can be used; the process of searching for effective 
monotherapies in patients at high risk can be avoided; and 
the BP target level can be reached more quickly. The need 
for combination therapy is particularly relevant for high-risk 
hypertensive patients such as those with diabetes or chronic 
kidney disease. A coexistent diagnosis of hypertension and 
diabetes increases the risk of adverse cardiovascular and renal 
outcomes, and the increased risk extends down to SBP/DBP 
levels as low as 127/83 mmHg.17
Results of numerous landmark clinical trials such 
as the VA Cooperative,18,19 HDFP,20 SHEP,21 Syst-Eur,22 
CONVINCE,23 INVEST,24 SCOPE,25 CAMELOT,26 VALUE,27 
ASCOT-BPLA,16 and ACCOMPLISH28 have demonstrated 
that several classes of antihypertensive agents, administered 
alone or most often in combination, can reduce BP and 
improve cardiovascular outcomes. Some evidence suggests 
that lowering elevated BP with antihypertensive therapy may 
also have a protective effect against vascular dementia and 
cognitive decline.4,29 Although a lack of benefit in this regard 
has also been reported, there is no empirical evidence to suggest 
that treatment of hypertension has negative effects on brain 
function, including in the very elderly.30,31 Antihypertensive 
regimens that suppress the renin-angiotensin-aldosterone 
system (RAAS) are of particular interest given the important 
role of the RAAS in cardiovascular and renal disorders and the 
ability of RAAS inhibitors to not only lower BP and reduce 
cardiovascular risk but to also provide organ protection.32,33 
Angiotensin receptor blockers (ARBs) have BP-lowering34 
and cardiorenal protective effects35–39 that are similar to those 
of angiotensin-converting enzyme (ACE) inhibitors, but with 
better tolerability.34 When ARBs are administered as part of 
combination therapy, an optimal approach is to include a 
diuretic or calcium channel blocker (CCB).40
In this review, we discuss the key studies that have assessed 
the antihypertensive effects of valsartan, one of the most 
extensively studied ARBs, when used in combination with the 
diuretic hydrochlorothiazide (HCTZ) or the CCB amlodipine 
in the first-line treatment of hypertension and its associated 
comorbidities. The studies described were not designed to 
assess clinical outcomes or effects on cognitive function. 
To date, studies involving amlodipine/valsartan have focused 
on BP control; outcomes studies are not available. In addition, 
no outcomes studies are available on the first-line use of 
valsartan/HCTZ, although a study in high-risk hypertensive 
patients in which HCTZ was a possible add-on therapy to 
valsartan demonstrated the benefits of this treatment on 
cardiovascular morbidity and mortality.27 Valsartan therapy 
has also shown benefits on hard endpoints in nonhypertensive 
populations including patients with chronic heart failure41 
and postmyocardial infarction.42 The latter part of this article 
presents patient-focused perspectives related to the use of 
valsartan/HCTZ and amlodipine/valsartan, along with a 
discussion of compliance in the treatment of hypertension 
and the rationale for the use of single-pill combinations.
Valsartan combination therapies
valsartan/hydrochlorothiazide (HCTZ)
The combination of valsartan/HCTZ is indicated in patients 
whose BP is not adequately controlled on monotherapy, and it 
is now also approved for use as first-line treatment in patients 
likely to need multiple drugs to achieve their BP goals. 
All studies discussed employed a randomized, double-blind 
design and, in all cases, study medication was administered 
once daily. A section on safety and tolerability follows the 
discussion of efficacy.
Mild to moderate hypertension
Phase III studies
Two  8-week,  placebo-controlled  studies  com-
pared  the  antihypertensive  efficacy  of  valsartan/
HCTZ versus monotherapy. In one study, 871 patients 
with mild to moderate hypertension, defined as DBP Integrated Blood Pressure Control 2009:2 41
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95–115 mmHg, were evaluated.43 Patients received valsartan/
HCTZ 80/12.5 mg, 80/25 mg, 160/12.5 mg, or 160/25 mg; 
valsartan 80 mg or 160 mg; HCTZ 12.5 mg or 25 mg; or 
placebo for 8 weeks. The primary endpoint was change in 
mean seated DBP (MSDBP) from baseline. Placebo-subtracted 
changes in mean seated SBP (MSSBP)/MSDBP from baseline 
to 8 weeks were −14.6/−7.7 mmHg, −19.2/−11.2 mmHg, 
−15.8/−9.4 mmHg, and −20.5/−11.2 mmHg with valsartan/
HCTZ 80/12.5 mg, 80/25 mg, 160/12.5 mg, and 160/25 mg, 
respectively; −6.9/−4.5 mmHg and −10.2/−5.3 mmHg with 
valsartan 80 mg and 160 mg, respectively; and −5.4/−3.0 mmHg 
and −10.8/−5.2 mmHg with HCTZ 12.5 mg and 25 mg, respec-
tively. Combination therapy provided significantly greater anti-
hypertensive efficacy relative to placebo and the corresponding 
monotherapies (P  0.05).
The second placebo-controlled study investigated the 
antihypertensive efficacy of valsartan and HCTZ alone and 
in combination at doses up to 320/25 mg in 1346 patients 
with DBP  95 mmHg and 110 mmHg.44 Patients 
received valsartan/HCTZ 160/12.5 mg, 320/12.5 mg, or 
320/25 mg; valsartan 160 mg or 320 mg; HCTZ 12.5 mg 
or 25 mg; or placebo for 8 weeks. The primary endpoint 
was change in MSDBP from baseline. Changes in MSSBP/
MSDBP from baseline to 8 weeks were −20.3/−15.2 mmHg, 
−21.7/−15.0 mmHg, and −24.7/−16.6 mmHg with valsartan/
HCTZ 160/12.5 mg, 320/12.5 mg, and 320/25 mg, respectively; 
−14.5/−11.7 mmHg and −13.7/−11.3 mmHg with valsartan 
160 mg and 320 mg, respectively; −11.1/−9.0 mmHg 
and −14.5/−10.8 mmHg with HCTZ 12.5 mg and 25 mg, 
respectively; and −5.9/−7.0 mmHg with placebo. Responder 
rates (MSDBP  90 mmHg or 10 mmHg reduction 
from baseline) and BP control rates (MSSBP/MSDBP 
140/90 mmHg) at endpoint are shown in Figure 1. For 
all efficacy parameters, combination therapy provided 
significantly greater antihypertensive efficacy relative to 
placebo and the corresponding monotherapies (P  0.05).
Phase Iv studies
The VELOCITY study assessed the BP reduction when 
initiating treatment with valsartan/HCTZ compared with 
initiating treatment with low-dose, conventional valsartan 
monotherapy (80 mg) or standard-dose valsartan mono-
therapy (160 mg) in 648 patients with mild to moderate 
hypertension (SBP/DBP 150–179/90–109 mmHg), including 
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systolic blood pressure [MSSBP]/MSDBP 140/90 mmHg) after 8 weeks of treatment in patients with mild to moderate hypertension. 
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patients with diabetes and metabolic syndrome.45 Patients 
received valsartan/HCTZ 160/12.5 mg, valsartan 80 mg, 
or valsartan 160 mg for 6 weeks. Patients were up-titrated 
after 2 and 4 weeks to the next dosage level (maximum 
for valsartan/HCTZ: 160/25 mg) only if MSSBP/MSDBP 
remained 140/90 mmHg. The primary endpoint was 
change in MSSBP from baseline to 2, 4, and 6 weeks. 
The level of BP reduction achieved in patients who began 
treatment with valsartan monotherapy (conventional step 
therapy) never caught up to the level achieved in patients who 
started with valsartan/HCTZ. Changes in MSSBP/MSDBP 
from baseline to 6 weeks were −27.1/−14.9 mmHg with 
valsartan/HCTZ, −20.1/−10.8 mmHg with valsartan 80 mg, 
and −23.1/−11.7 mmHg with valsartan 160 mg. Results 
favored combination therapy over either dose of valsartan 
alone (P  0.05).
The PROMPT study compared the antihypertensive 
efficacy of valsartan/HCTZ (first- and second-line use) and 
amlodipine/HCTZ for maximizing BP control in 1285 patients 
with uncontrolled hypertension.46 Patients who had mild 
hypertension (SBP/DBP 140–159/90–99 mmHg) and were 
naïve to antihypertensive therapy started on valsartan 160 mg 
or amlodipine 5 mg. Treatment-naïve patients with moderate 
hypertension (SBP/DBP 160–179/100–109 mmHg) and 
those uncontrolled on current antihypertensive monotherapy 
started on valsartan/HCTZ 160/12.5 mg or amlodipine 10 mg. 
At 4, 8, and 11 weeks, patients not achieving BP control 
were uptitrated (maximum: valsartan/HCTZ 320/25 mg or 
amlodipine/HCTZ 10/25 mg). Uptitration was mandatory for 
MSSBP/MSDBP  140/90 mmHg. The treatment duration was 
14 weeks. BP control rates (MSSBP/MSDBP  140/90 mmHg) 
at 14 weeks, the primary endpoint, were 78.8% with 
valsartan-based treatment and 67.8% with amlodipine-based 
treatment (P  0.0001). Significant differences in favor of 
valsartan-based therapy were observed as early as 8 weeks 
(70.3% vs 64.5%, P  0.05). Results were consistent, regardless 
of whether patients were treatment naïve or had failed previous 
monotherapy. Thus, the valsartan-based strategy was superior to 
the amlodipine-based strategy for achieving BP control.
Moderate hypertension
The EVALUATE study examined the antihypertensive efficacy 
of valsartan/HCTZ and amlodipine/HCTZ on the reduction 
of ambulatory BP (ABP) in 482 patients with moderate 
hypertension (SBP 160–200 mmHg).47 EVALUATE was 
designed to mirror the treatment arms of the VALUE outcomes 
study. In VALUE, there was greater BP reduction observed in 
the amlodipine arm compared with the valsartan arm in the 
first 6 months that accounted for the differences in outcomes 
favoring amlodipine.27 It is discussed that these findings may 
have been due to slow titration and use of a less than maximal 
dose of valsartan (160 mg),48 which is half of what is currently 
considered as the maximum recommended dose. Thus, in 
EVALUATE, patients received valsartan 160 mg force-titrated 
to valsartan/HCTZ 160/12.5 mg at 2 weeks and 320/25 mg at 
6 weeks or amlodipine 5 mg force-titrated to 10 mg at 2 weeks 
and amlodipine/HCTZ 10/25 mg at 6 weeks.47 The treatment 
duration was 10 weeks. The primary endpoint was change 
in mean 24-hour ambulatory SBP (ASBP) from baseline to 
10 weeks. Changes in mean 24-hour ASBP/ambulatory DBP 
(ADBP) from baseline to 10 weeks were −21.1/−12.5 mmHg 
with valsartan/HCTZ and −18.1/−9.9 mmHg with amlodipine/
HCTZ (P  0.01). As shown in Figure 2, valsartan/HCTZ 
provided greater antihypertensive efficacy over the entire 
24-hour monitoring period. ABP control rates (mean 24-hour 
ASBP/ADBP  130/80 mmHg) at 10 weeks were 54.3% 
with valsartan/HCTZ and 42.7% with amlodipine/HCTZ 
(P  0.05). These data show that valsartan/HCTZ provides 
reduction in ABP that is superior to that achieved with 
amlodipine/HCTZ.
Severe hypertension
In the CDITT study, the antihypertensive efficacy of initiating 
therapy with combination valsartan/HCTZ versus valsartan 
monotherapy was examined in 608 patients with severe 
hypertension, defined as SBP  140 mmHg and 200 mmHg 
plus DBP  110 mmHg and 120 mmHg.49 Patients received 
valsartan/HCTZ 160/12.5 mg force-titrated to 160/25 mg at 
2 weeks and 320/25 mg at 4 weeks or valsartan 160 mg force-
titrated to 320 mg at 2 weeks and sham-titrated to 320 mg at 
4 weeks. The treatment duration was 6 weeks. BP control rates 
(MSSBP/MSDBP  140/90 mmHg) at 4 weeks, the primary 
endpoint, were 39.6% with valsartan/HCTZ and 21.8% with 
valsartan (P  0.0001). The corresponding results at 6 weeks 
were 48.2% and 27.2% (P  0.0001). Changes in MSSBP/
MSDBP from baseline to 4 weeks and 6 weeks are shown 
in Figure 3. Control rates and BP reductions consistently 
favored combination therapy over monotherapy, regardless 
of age (65 or 65 years), race (white or black), or severity 
of baseline MSSBP (180 or 180 mmHg).
Influence of valsartan on the metabolic effects  
of HCTZ in the combination valsartan/HCTZ
The MADE-ITT study evaluated the effects of valsartan 
and HCTZ alone and in combination on insulin sensitivity 
and inflammatory/metabolic biomarkers in 566 patients Integrated Blood Pressure Control 2009:2 43
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with prediabetes, obesity, hypertension (SBP/DBP 
130–160/85–100 mmHg) and the cardiometabolic syndrome.50 
Patients received valsartan/HCTZ 160/12.5 mg force-titrated 
to 320/25 mg at 2 weeks, valsartan 160 mg force-titrated to 
320 mg at 2 weeks, or HCTZ 12.5 mg force-titrated to 25 mg 
at 2 weeks. The treatment duration was 16 weeks. There were 
no significant differences among the 3 treatment groups for 
the primary endpoint, which was change in homeostasis model 
assessment-insulin resistance (HOMA-IR) from baseline 
to 16 weeks. However, valsartan attenuated the negative 
metabolic effects of HCTZ (increases in triglyceride and 
hemoglobin). At 16 weeks, treatment with HCTZ increased 
triglyceride levels by 0.3 mmol/L and hemoglobin A1c levels 
by 0.2%, whereas valsartan and valsartan/HCTZ had less of 
an effect on these parameters. Changes in MSSBP/MSDBP 
from baseline to 16 weeks were significantly greater with 
combination therapy (−20/−12 mmHg) than with valsartan 
(−14/−9 mmHg) or HCTZ (−12/−7 mmHg) (P  0.0001). 
These findings support the initial use of valsartan/HCTZ in 
this high-risk population.
The VITAE study was undertaken to confirm the findings 
from MADE-ITT using actual glucose and insulin measures 
(both fasting and 2 hour).51 Specifically, the metabolic 
and antihypertensive effects of valsartan/HCTZ versus 
amlodipine/HCTZ in 412 prediabetic, obese patients with mild 
to moderate hypertension (SBP/DBP 150–179/110 mmHg) 
were investigated. Patients received valsartan/HCTZ 
160/12.5 mg force-titrated to 320/12.5 mg at 4 weeks and 
320/25 mg at 8 weeks, or HCTZ 12.5 mg force-titrated to 
25 mg at 4 weeks, amlodipine/HCTZ 5/25 mg at 8 weeks, 
and amlodipine/HCTZ 10/25 mg at 12 weeks. The treatment 
duration was 16 weeks. The primary endpoint was change 
in MSSBP from baseline. Changes in MSSBP/MSDBP 
from baseline to 16 weeks were −30.6/−14.0 mmHg with 
valsartan/HCTZ and −28.3/−12.7 mmHg with amlodipine/
HCTZ (P = NS). Fasting and 2-hour glucose increased 
with amlodipine/HCTZ compared with valsartan/HCTZ 
(P  0.01), resulting in a greater percentage of patients with 
impaired fasting glucose or impaired oral glucose tolerance 
test. In the valsartan/HCTZ group, the percentage of patients 
with impaired fasting glucose was 34% at baseline and 38% 
at 16 weeks. Corresponding results for impaired oral glucose 
tolerance test were 36% and 29%. Conversely, the percentage 
of amlodipine/HCTZ-treated patients with impaired fasting 
glucose increased from 38% to 50% during this time as did 
the percentage with impaired oral glucose tolerance test (from 
34% to 48%). New-onset diabetes occurred in more patients 
receiving amlodipine/HCTZ compared with valsartan/HCTZ 
(11% vs 2%, P  0.05). Thus, compared with amlodipine/
HCTZ, valsartan/HCTZ reduced progression towards 
impaired fasting glucose, impaired glucose tolerance, and 
new-onset diabetes in this high-risk population.
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Switch study
Diuretics are recommended as first-line therapy for the 
treatment of hypertension.2,15 A study was conducted to assess 
whether, in patients uncontrolled on diuretic monotherapy, 
it is a better strategy to switch to dual therapy or double 
the dose of diuretic.52 The Val-DICTATE study included 
291 patients with hypertension whose BP remained uncon-
trolled (SBP  140 and 180 mmHg plus DBP  90 
and 110 mmHg) after 4 weeks of therapy with low-dose 
HCTZ (12.5 mg). These patients received valsartan/HCTZ 
(160/12.5 mg) or double the dose of HCTZ (25 mg) for 
another 4 weeks. At study end, a significantly greater 
percentage of patients achieved the BP goal (MSSBP/
MSDBP  140/90 mmHg), the primary endpoint, in the 
valsartan/HCTZ group compared with the high-dose HCTZ 
group (36.6% vs 15.9%, P  0.0001). Similarly, changes 
in MSSBP/MSDBP at study end were significantly greater 
in the combination therapy arm compared with the diuretic 
monotherapy arm (−12.4/−7.5 mmHg vs −5.6/−2.1 mmHg, 
P  0.0001). Thus, in patients whose BP was inadequately Integrated Blood Pressure Control 2009:2 45
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controlled on low-dose HCTZ (12.5 mg), switching to 
valsartan/HCTZ 160/12.5 mg was a better antihypertensive 
strategy than doubling the dose of HCTZ.
Other studies
The results of several open-label studies also support the 
antihypertensive efficacy of valsartan/HCTZ.44,53–58
Safety and tolerability
The combination of valsartan/HCTZ is well tolerated 
and adverse events are generally mild and transient. 
A meta-analysis of the results of 9 randomized, double-blind, 
placebo-controlled, hypertension studies (N = 4278) of once-
daily valsartan 80, 160, or 320 mg or valsartan/HCTZ 80/12.5, 
160/12.5 mg, 160/25 mg, 320/12.5 mg, or 320/25 mg given 
for 4 to 8 weeks found that the most common adverse event 
was dizziness (7.3% to 16.0% in the valsartan/HCTZ groups 
vs 2.4% to 5.2% with valsartan monotherapy and 2.8% with 
placebo).59 The incidence of headache was similar across all 
dose groups including placebo. The rate of discontinuation 
due to adverse events was generally low at all dose levels 
(eg, 3.0% with valsartan/HCTZ 320/25 mg vs 2.7% with 
placebo).59 Data suggest that the incidence of hypokalemia 
may be lower with valsartan/HCTZ compared with HCTZ 
alone (1.8% to 6.1% vs 7.1% to 13.3%),44 and that valsartan 
may attenuate the negative metabolic effects of HCTZ in 
patients with prediabetes, obesity, hypertension, and the 
cardiometabolic syndrome (see MADE-ITT study results 
described previously).50 Valsartan/HCTZ was associated 
with a lower incidence of peripheral edema compared with 
amlodipine/HCTZ across the studies presented previously 
(1.5% to 3.3% vs 9.7% to 22.4%).46,47,51
Amlodipine/valsartan
The combination of amlodipine/valsartan is indicated for 
the treatment of hypertension in patients not adequately 
controlled on monotherapy and as initial therapy in patients 
likely to need multiple drugs to achieve their BP goals. All 
studies discussed in this section employed a randomized, 
double-blind design and, in all cases, study medication was 
administered once daily. A section on safety and tolerability 
follows the discussion of efficacy.
Factorial phase III studies in mild to moderate 
hypertension
Two placebo-controlled studies compared the antihypertensive 
efficacy of various combinations of amlodipine/valsartan 
versus monotherapy with these agents in 3161 patients with 
mild to moderate hypertension (DBP  95 and 110 mmHg).60 
In study 1, 15 factorial treatment regimens were used and, 
in study 2, 6 regimens were used. The primary endpoint was 
change in MSDBP from baseline to 8 weeks. Apart from 
a few combinations that included amlodipine 2.5 mg, the 
combination regimens in both studies were associated with 
significantly greater reductions in MSSBP and MSDBP 
compared with their individual components and placebo 
(P  0.05). A positive dose-response relationship was 
observed for all combinations, and the highest response 
rate (MSDBP  90 mmHg or a 10 mmHg reduction from 
baseline) in study 1 was associated with the highest dose 
of combination therapy (91.3% for amlodipine/valsartan 
5/320 mg). In contrast, amlodipine 5 mg, valsartan 320 mg, 
and placebo as monotherapy were associated with response 
rates of 71.9%, 73.4%, and 40.9%, respectively. In study 2, the 
2 combination therapy regimens were associated with similar 
response rates (amlodipine/valsartan 10/160 mg, 88.5%; 
amlodipine/valsartan 10/320 mg, 87.5%). Amlodipine 10 mg 
was associated with a response rate of 86.9%; valsartan 
160 mg and 320 mg were associated with response rates 
of 74.9% and 72.0%, respectively. Placebo was associated 
with a response rate of 49.3%.60 Subgroup analyses of the 
results of these studies, conducted according to the severity 
of hypertension (mild or moderate), age (65 or 65 years) 
and race (white or black), showed that reductions in MSSBP 
and MSDBP in the various subgroups were consistent with 
the findings from the overall study population.61
Phase Iv studies in moderate hypertension
Destro and colleagues investigated the antihypertensive 
efficacy of amlodipine/valsartan and amlodipine alone in 
646 patients with moderate hypertension (SBP  160 mmHg 
and 200 mmHg).62 Patients received amlodipine/valsartan 
5/160 mg force-titrated to 10/160 mg at 2 weeks or amlodipine 
5 mg force-titrated to 10 mg at 2 weeks. HCTZ was optionally 
added at 4 weeks in patients if MSSBP  130 mmHg. The 
treatment duration was 8 weeks. Changes in MSSBP from 
baseline to 4 weeks (prior to possible addition of HCTZ), the 
primary endpoint, were −30.1 mmHg with amlodipine/valsartan 
and −23.5 mmHg with amlodipine (P  0.0001). In patients 
with baseline MSSBP  180 mmHg, the corresponding 
results were −40.1 mmHg and −31.7 mmHg (P  0.01). 
Results were consistent across various patient subgroups, 
including patients with diabetes, the elderly (65 years), 
patients with isolated systolic hypertension, those with body 
mass index 30 kg/m2, and patients of different races/
ethnicity (white, black, or Hispanic) (Figure 4). BP control Integrated Blood Pressure Control 2009:2 46
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rates (MSSBP/MSDBP 140/90 mmHg) at 4 weeks were 
45.3% with amlodipine/valsartan and 23.8% with amlodipine 
(P  0.0001).
Poldermans and colleagues examined the antihyper-
tensive efficacy of amlodipine/valsartan compared with 
lisinopril/HCTZ in 130 patients with moderate hyperten-
sion (DBP  110 mmHg and 120 mmHg).63 Patients 
received amlodipine/valsartan 5/160 mg or lisinopril/
HCTZ 10/12.5 mg for 2 weeks. Thereafter, up-titration 
to 10/160 mg and 20/12.5 mg, respectively, occurred for 
MSDBP  90 mmHg. The treatment duration was 6 weeks. 
The primary endpoint was safety, but post-hoc efficacy end-
points included change in MSSBP/MSDBP from baseline 
and BP control rates (MSSBP/MSDBP  140/90 mmHg). 
Both regimens were deemed efficacious. Changes in MSSBP/
MSDBP from baseline to study end were −35.8/−28.6 mmHg 
with amlodipine/valsartan and −31.8/−27.6 mmHg with 
lisinopril/HCTZ. BP control rates at this time were 67.2% 
and 56.1%, respectively.
Phase Iv study in black patients with moderate 
hypertension
Blacks patients are usually considered a difficult-to-
treat population. The EX-STAND study assessed the 
antihypertensive efficacy of initiating treatment with 
amlodipine/valsartan compared with amlodipine mono-
therapy in 572 black patients with moderate hyperten-
sion (SBP  160 and 200 mmHg).64 Patients received 
amlodipine/valsartan 5/160 mg force-titrated to 10/160 mg 
at 2 weeks or amlodipine 5 mg force-titrated to 10 mg at 
2 weeks. If MSSBP was  130 mmHg at 4 weeks, the doses 
in the amlodipine/valsartan arm were increased to 10/320 mg 
and placebo was added to the amlodipine arm. At 8 weeks, 
HCTZ was optionally added to both treatment groups for 
patients with MSSBP 130 mmHg. The treatment dura-
tion was 12 weeks. Changes in MSSBP from baseline to 
8 weeks (prior to possible addition of HCTZ), the primary 
endpoint, were −33.3 mmHg with amlodipine/valsartan and 
−26.6 mmHg with amlodipine (P  0.0001). Significant 
differences in favor of initial combination therapy were 
observed as early as 2 weeks and also were seen at 4 and 
12 weeks (Figure 5). Combination therapy provided greater 
reductions in MSSBP from baseline to 8 weeks across various 
patient subgroups, including the elderly (65 years), patients 
with isolated systolic hypertension, diabetics, those with 
body mass index 30 kg/m2, patients who were black/
Hispanic, and patients with baseline MSSBP  180 mmHg. 
BP control rates (MSSBP/MSDBP  140/90 mmHg) at 
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Figure 4 Least-squares mean changes in mean seated systolic blood pressure (MSSBP) from baseline after 4 weeks of treatment across various patient subgroups with moderate 
hypertension. elderly patients were 65 years of age. 
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8 weeks were 49.8% with amlodipine/valsartan and 30.2% 
with amlodipine (P  0.0001).
Phase IIIB-Iv switch studies in patients previously 
uncontrolled with monotherapy
Allemann and colleagues evaluated the antihypertensive 
efficacy of a strategy involving a direct switch to amlodipine/
valsartan in 894 patients whose BP was uncontrolled by 
previous monotherapy (EX-FAST study).65 Patients were 
switched directly to amlodipine/valsartan 5/160 mg or 
10/160 mg for 16 weeks. At 8 weeks, HCTZ was added 
to both treatment groups for patients whose BP was not 
controlled (MSSBP/MSDBP  140/90 mmHg in nondiabetic 
patients, 130/80 mmHg in patients with diabetes). 
BP control rates at 16 weeks, the primary endpoint, were 
similar in the 2 treatment groups: 72.7% with amlodipine/
valsartan 5/160 mg (± HCTZ) and 74.8% with amlodipine/
valsartan 10/160 mg (± HCTZ). Incremental reductions in 
MSSBP/MSDBP from baseline to 16 weeks were significantly 
greater with the higher dose (−20.0/−11.6 mmHg) than with 
the lower dose (−17.5/−10.4 mmHg) (P  0.01). BP control 
rates at 8 weeks (prior to possible addition of HCTZ) also were 
significantly greater with the higher dose (76.4%) than with the 
lower dose (71.1%) (P  0.05). Subgroup analysis revealed 
that the antihypertensive efficacy of amlodipine/valsartan 
was well maintained regardless of previous antihypertensive 
monotherapy (Figure 6), baseline hypertension severity, 
diabetic status, body mass index, age, gender, or race.
The antihypertensive efficacy of switching patients whose 
BP was not controlled on valsartan 160 mg monotherapy to 
amlodipine/valsartan 5/160 mg or 10/160 mg was studied in 
947 patients with mild or moderate hypertension (DBP  95 
and 110 mmHg).66 Patients received amlodipine/valsartan 
5/160 mg, amlodipine/valsartan 10/160 mg, or continued 
on valsartan 160 mg for 8 weeks. The primary endpoint was 
change in MSDBP from baseline to study end. Changes 
in MSSBP/MSDBP from baseline to study end were 
significantly greater with lower-dose combination therapy 
(−12.2/−9.6  mmHg)  and  higher-dose  combination 
therapy (−14.3/−11.5 mmHg) compared with valsartan 
alone (−8.3/−6.7 mmHg) (P  0.0001). The 10/160 mg 
combination showed significantly greater reductions in MSSBP 
and MSDBP than the 5/160 mg combination (P  0.05). 
Response rates (MSDBP 90 mmHg or 10-mmHg 
reduction from baseline) at endpoint were significantly greater 
in the combination therapy groups (68% with 5/160 mg, 
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81% with 10/160 mg) than in the monotherapy group (57%) 
(P  0.01). Both combination therapies were more effective 
than monotherapy regardless of age (65 or 65 years).
Other studies
The results of several open-label studies also support the 
antihypertensive efficacy of amlodipine/valsartan.67–72 
Of note, one of the trial designs involved switching patients 
whose BP was not controlled on a free combination 
(amlodipine plus olmesartan) to a single-pill combination 
(amlodipine plus valsartan).71 Treatment with the single-
pill combination was associated with a further reduction 
in BP of 7.9/9.1 mmHg, with 42% of previously uncon-
trolled patients achieving BP  140/90 mmHg. The authors 
concluded that these results may have been related, at least in 
part, to improved patient compliance, although this was not 
specifically assessed in the study. The issues of compliance 
with antihypertensive therapy and the potential role of single-
pill combination therapy are discussed in more detail later.
Safety and tolerability
Amlodipine/valsartan was well tolerated in the above-
mentioned clinical studies. Most adverse events were mild 
or moderate in severity and did not result in discontinuation. 
Overall, the most frequent adverse event was peripheral 
edema, which is a well-known side effect of CCBs. CCBs 
cause greater dilation of the arteriolar rather than the venous 
circulation, giving rise to an increased transcapillary gradient 
and capillary leakage.73 The addition of a RAAS blocker may 
help to negate this effect because it causes dilation of both 
arterial and venous capillary beds, thus bringing transcapillary 
pressure back to normal. One randomized, double-blind study 
assessed the incidence of peripheral edema as a co-primary 
endpoint in 1183 patients not adequately controlled on 
amlodipine 5 mg.74 Peripheral edema was evaluated at every 
clinic visit and was based on spontaneous reports by the 
patients and on the presence of signs of edema on physical 
examination of the patient by the investigator. Over the first 
8 weeks of the study, patients received either amlodipine/
valsartan 5/160 mg or double the dose of amlodipine (10 mg). 
During this time, peripheral edema was reported in 31.1% 
of patients on high-dose amlodipine compared with only 
6.6% of patients on combination therapy (P  0.001). After 
8 weeks of therapy, 484 patients previously on high-dose 
amlodipine were switched to amlodipine/valsartan 5/160 mg 
for another 4 weeks. Of the 79 patients who had peripheral 
edema entering the switch phase, 44 (56%) had resolution of 
this adverse event during the switch phase. In the double-blind 
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studies described previously, peripheral edema was reported 
in a slightly higher percentage of amlodipine-treated 
(± HCTZ) patients (8.7% to 17.6%) than amlodipine/
valsartan-treated (± HCTZ) patients (5.0% to 16.7%). The 
occurrence of peripheral edema appeared to be related to 
the dose of amlodipine. The incidence of peripheral edema 
was low among patients treated with valsartan monotherapy 
(1.3% to 2.1%) or placebo (3%) in the same studies.
Patient-focused perspectives
Much of the difficulty of controlling high BP may be due to 
poor persistence and adherence with therapy as patients who 
are adherent are more likely to have good BP control.75 Poor 
adherence with antihypertensive therapy may lead to extra 
medical consultations, higher doses, or an increase in the number 
of medications used and possibly increased morbidity and 
mortality, loss of productivity, and increased health care costs. 
Analyses of data from the Integrated Healthcare Information 
Solutions (IHCIS) National Managed Care Benchmark 
Database indicate that patient compliance improves with 
simplification of pharmacotherapeutic approaches,76 and that 
use of single-pill combination therapy may improve adherence 
and persistence and have a positive economic impact.77
For example, an analysis of the impact of multiple com-
bination therapies on medication possession ratios (MPRs) 
in an antihypertensive-naive population was conducted 
using IHCIS data from patients treated with valsartan or 
valsartan/HCTZ in a single-pill combination plus amlodipine 
(2-pill therapy) compared with patients who received 3-pill 
therapy with valsartan plus HCTZ plus amlodipine.76 Data 
from 908 patients were included (2-pill therapy with valsartan 
plus amlodipine, n = 224; 2-pill therapy with valsartan/HCTZ 
plus amlodipine, n = 619; and 3-pill therapy with valsartan 
plus HCTZ plus amlodipine, n = 65) over a 1-year study 
period. MPR values obtained were 75.4%, 73.1%, and 
60.5%, respectively (P  0.01), and it was found that MPR 
improved with age (69.6% in the subset aged 18 to 36 years 
vs 75.2% in the subset aged 64 years, P  0.05). Thus, 
in these antihypertensive-naive patients with hypertension, 
MPR decreased with the increase in tablets per regimen. 
Improved MPR was correlated with increasing age, and the 
results suggested that patient compliance improved with 
simplified pharmacotherapeutic approaches.
In addition, medical and prescription claims for hyper-
tensive patients were identified from the IHCIS National 
Managed Care Benchmark Database via a retrospective 
cohort analysis to assess medication adherence, persistence, 
and costs between cohorts of patients in managed care 
settings using a single-pill combination of valsartan/HCTZ 
or the individual components.77 Patients who were studied 
had at least 110 days prior to start of study medications 
during which no other antihypertensive medications were 
prescribed, were followed for 12 months, and claims for 
8711 adult patients were analyzed. Most individuals used a 
single-pill combination product (n = 8150, 93.6%) versus the 
individual components (n = 561, 6.4%). A random sample 
of 1628 of the single-pill combination patients showed 
improved values for medication adherence compared with 
the individual components group (62% vs 53%, P  0.001), 
and persistence values were improved at both 180 days 
(73% vs 28%, P  0.001) and 365 days (54% vs 19%, 
P0.001). Both prescription drug costs and medical costs 
were significantly lower in the single-pill combination cohort. 
Over 1 year, the mean total prescription costs for the indi-
vidual components versus the single-pill combination were 
US$2050 versus US$1587, respectively, providing a mean 
difference of $463 (P  0.001). Corresponding medical costs 
were US$3817 versus US$3343, providing a mean difference 
of US$474 (P  0.001). Although unobserved systematic 
differences between the 2 medication groups may have 
existed, as with any retrospective claims database analysis, 
it was concluded that use of valsartan/HCTZ single-pill 
combination therapy in hypertension may lead to increased 
adherence and persistence with a positive financial impact 
on both prescription and total medical costs. Combination 
therapy with a CCB plus an ARB also was shown to be a 
more cost-effective lifetime antihypertensive strategy than 
monotherapy with either agent alone.78
Compliance in the treatment  
of hypertension
Hypertension is a common and extremely treatable risk factor 
for major cardiovascular events and cerebrovascular events. 
Since together they represent a major cause of morbidity 
and mortality throughout the developed world, and in many 
developing nations, one would assume that once a large 
number of safe and effective medications were developed 
and widely distributed at reasonable costs, the problem 
represented by hypertension would gradually diminish to the 
point of being irrelevant. In fact that has not occurred, and 
it is useful to examine compliance and its politically correct 
alternative of adherence.
Any consideration must include an analysis of the 
problem, its consequences, and suggestive approaches 
to its resolution or improvement. There is little doubt 
about the size of the problem of poor compliance with Integrated Blood Pressure Control 2009:2 50
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antihypertensive therapy. In a recent Italian study, a cohort 
of 445,356 hypertensive patients aged 40–80 years received 
their first antihypertensive prescription (monotherapy) 
during 1999–2002.79 Discontinuation was defined by the 
absence of any antihypertensive therapy during a 90-day 
period following the end of the last prescription. If during 
the same period a drug of a different class was added or 
replaced the original prescription, the treatment modification 
was considered combination or switching, respectively. The 
cumulative incidences of discontinuation, combination, and 
switching were 41%, 18%, and 17% at 1 year and 50%, 
25%, and 19% at 5 years, and inhibitors of the RAAS were 
associated with the lowest rates of discontinuation.79 Drug 
choice apparently does affect the compliance with treatment 
options and outcomes in elderly hypertensive patients.80 
A prospective, single-center study focused on elderly patients 
and utilized a full range of currently available drugs, which 
added to its relevance.81 The authors found that newer 
antihypertensive therapies, including ACE inhibitors and 
ARBs, were associated with greater persistence and better 
antihypertensive efficacy than older drugs. At the end of the 
2-year study, patients who started on diuretics were only half 
as likely to be still taking their medication compared with 
the more modern drugs. In addition to the importance of 
class of antihypertensive therapy, it is critical for physicians 
to diagnose any cognitive impairment that may exist in the 
elderly patient, as this may have important implications in 
terms of treatment compliance.30
Because hypertension control rates are unsatisfactory, 
the role of adherence has been examined. A variety of 
programs have been suggested including patient motivational 
factors, social support, and reminding techniques.82 For 
example, a program that included a combination of medical 
education, regular follow-up by pharmacists, and time-specific 
medication packs yielded an overall 34% improvement in 
medication adherence and significant reductions in SBP of 
6.9 mmHg.83 Other approaches have included simpler dosing, 
various drug packaging, and provider interventions including 
tutorials. In general, although there are some occasional success 
stories, it is apparent that as yet we have not discovered the 
“magic bullet” that will ensure appropriate compliance.84
The rationale for combination 
antihypertensive therapy including 
single-pill combinations
Control of hypertension is difficult to achieve in clinical 
practice, especially in high-risk patients, and so-called 
‘therapeutic inertia’ derived from poorly prescribed 
lifestyle changes, excessive use of monotherapy, and scarce 
on-treatment modifications may be a significant factor.85 
The use of combination therapy and, in particular, single-pill 
combinations, significantly improves BP control without 
increasing daily pill intake, favoring patient compliance, 
continuity of treatment, and lower costs to the health care 
system.2,85–87 For example, a recent retrospective analysis of 
medical and pharmacy claims data found that, compared 
with free-combination antihypertensive therapy, single-pill 
combination therapy resulted in 42.5% greater persistence, 
22.1% greater compliance, 21.3% fewer hypertension-related 
hospitalizations, and 20.2% lower expenditures for 
hypertension-related services.88 Other analyses have similarly 
demonstrated that subjects taking single-pill combination 
antihypertensive therapy had significant increases in medica-
tion adherence and reductions in resource utilization rela-
tive to subjects receiving the same drug classes as separate 
components.89,90 A meta-analysis by Bangalore and colleagues 
found that single-pill combination therapy reduced the risk 
of medication nonadherence among hypertensive patients by 
24% compared with free-combination therapy.91 Consistent 
with these findings, current hypertension treatment guidelines 
recommend single-pill combination therapy in appropriate 
patients, based on its ability to simplify the treatment 
schedule and optimize compliance.2
Conclusions
In conclusion, the results indicate that both valsartan/HCTZ 
and amlodipine/valsartan are excellent options for a broad 
range of hypertensive patients, including difficult-to-treat 
populations such as those with severe BP elevations, 
diabetes (and prediabetes), patients with the cardiometabolic 
syndrome, and individuals who are obese, elderly, or black. 
BP reductions with these combinations are greater than 
with the different monotherapy components alone, and both 
combinations are now indicated for first-line use in patients 
likely to need multiple drugs to achieve their BP goals. 
Although not discussed here, the clinician also has a number 
of other ARB-based single-pill combination treatments avail-
able (see Table 1) to ensure that a majority of patients with 
hypertension can attain their BP targets in a timely manner. 
These ARB-based combinations have the added advantage 
of good tolerability, with the ARB potentially reducing the 
adverse metabolic effects of HCTZ and the peripheral edema 
that may be associated with amlodipine.
Current treatment guidelines recommend first-line 
combination therapy for patients with stage 2 hypertension Integrated Blood Pressure Control 2009:2 51
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(SBP  160 mmHg and/or DBP  100 mmHg) or at high 
risk for cardiovascular events.2,15 ARB/diuretic or CCB/
ARB combinations would be beneficial for most of these 
patients. In particular, RAAS inhibitor-based treatments 
are the preferred option for high-risk hypertensive patients 
with diabetes, metabolic syndrome, or kidney disease, for 
example. Some data suggest that black patients, who tend to 
have more severe hypertension than other racial groups,92 may 
respond less favorably than nonblacks to RAAS inhibitors.93 
However, the need for combination therapy in a majority 
of black patients renders any differences in response to 
monotherapy inconsequential.94,95 The increased risk for 
ACE inhibitor-induced cough and angioedema among 
black patients94 may make ARB-based combinations more 
attractive.
Whether certain hypertensive populations will benefit 
more from one particular combination over another depends on 
several patient-related factors. For example, valsartan/HCTZ 
(or other ARB/HCTZ combinations) may be an adequate option 
for hypertensive patients without insulin resistance, whereas a 
CCB/RAAS blocker may be a preferred combination for the 
population with prediabetes, many of whom will need multiple 
antihypertensive agents.96 Diuretics are not preferred first-line 
treatment in patients with prediabetes or diabetes due to their 
negative metabolic effects. The findings of ACCOMPLISH, 
which included 11,506 patients (mean age, 68 years) with 
hypertension (mean baseline SBP/DBP, 145/80 mmHg) and 
high cardiovascular risk secondary to previous major events 
or presence of diabetes, suggest that a CCB/RAAS blocker 
combination may be a better option than a diuretic/RAAS 
blocker combination for this high-risk population.28
In the future, novel RAAS-based combination therapies 
may become available (eg, dual inhibition of AT1/endothelin 
receptors, AT1/thromboxane A2 receptors, and ACE/neutral 
endopeptidase).97 Further simplification of therapy and 
optimization of adherence may result from the incorporation 
of three drugs into a single pill.98 In addition, the possible 
benefits of combination antihypertensive therapy in reducing 
the risk of vascular dementia and cognitive dysfunction will 
undoubtedly be a focus of upcoming research.
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